MAIA Biotechnology, Inc.

NYSE American MAIA

MAIA Biotechnology, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024

MAIA Biotechnology, Inc. Debt to Equity Ratio is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NYSE American: MAIA

MAIA Biotechnology, Inc.

CEO	Dr. Vlad Vitoc M.B.A., M.D.
IPO Date	July 28, 2022
Location	United States
Headquarters	444 West Lake Street
Employees	13
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Key trends

Past 5 years